포도막염 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 질환 유형별, 원인별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Uveitis Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Disease Type, by Cause, By Distribution Channel, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,169,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,541,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 10,968,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 포도막염 치료제 시장은 2024년 7억 530만 달러로 평가되며, 2030년까지 CAGR은 7.20%로 예측 기간 동안 괄목할 만한 성장을 이룰 것으로 예상됩니다.

포도막염은 홍채, 모양체, 맥락막을 포함한 안구의 중간층인 포도막에 영향을 미치는 염증성 안질환군을 말합니다. 포도막염을 방치하면 심각한 시력장애나 실명에 이를 수 있습니다. 이 질환은 감염, 자가면역질환, 외상에 의해 유발되는 경우와 특발성일 수 있습니다. 주요 증상으로는 눈의 통증, 충혈, 눈부심, 눈부심, 빛 과민증, 부유감 등이 있습니다. 전 세계적으로 고령화 사회가 진행되면서 노화에 따른 안질환이 만연함에 따라 효과적인 포도막염 치료에 대한 수요가 증가하고 있습니다. 치료제의 발전은 인식의 증가와 진단 능력의 향상과 함께 시장 확대를 더욱 촉진하고 있습니다. 세계보건기구(WHO)에 따르면, 60세 이상 인구는 2015년 9억 명에서 2050년까지 20억 명으로 증가할 것으로 예상되며, 이로 인해 포도막염과 같은 안질환의 부담이 증가하여 효과적인 약물 치료의 필요성이 증가하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	7억 530만 달러
시장 규모 : 2030년	10억 6,182만 달러
CAGR : 2025-2030년	7.20%
급성장 부문	온라인 약국
최대 시장	북미

주요 시장 촉진요인

치료 옵션의 발전

주요 시장 과제

치료비 폭등

주요 시장 동향

환자 중심적 접근

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 포도막염 치료제 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별(진통제, 항생제, 항진균제, 항바이러스제, 코르티코스테로이드, 모세혈관 확장제, 면역억제제, 단클론항체)
  • 질환 유형별(전부 포도막염, 중간부 포도막염, 범포도막염, 후부 포도막염)
  • 원인별(감염성, 비감염성)
  • 유통 채널별(병원 약국, 온라인 약국, 소매 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 포도막염 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 포도막염 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 포도막염 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제9장 남미의 포도막염 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 포도막염 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제13장 세계의 포도막염 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Allergan Inc
• Bausch & Lomb Incorporated
• Santen Pharmaceutical Co Ltd.
• AbbVie Inc.
• Novartis AG
• Eyegate Pharmaceuticals;Inc.
• Regeneron Pharmaceuticals
• Eyepoint pharmaceuticals Inc.
• Alimera Sciences Inc.

제17장 전략적 제안

제18장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

Global Uveitis Drugs Market was valued at USD 705.30 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.20% through 2030F. Uveitis refers to a group of inflammatory eye conditions affecting the uvea, the eye's middle layer, which includes the iris, ciliary body, and choroid. If left untreated, uveitis can lead to serious vision impairment or even blindness. The condition may be caused by infections, autoimmune disorders, trauma, or may be idiopathic. Key symptoms include eye pain, redness, blurred vision, light sensitivity, and floaters. With the global aging population on the rise and age-related eye disorders becoming more prevalent, demand for effective uveitis treatments is increasing. Advances in therapeutic formulations, coupled with heightened awareness and improved diagnostic capabilities, are further supporting market expansion. According to the World Health Organization, the population aged 60 and over is expected to grow from 900 million in 2015 to 2 billion by 2050, increasing the burden of ocular diseases such as uveitis and driving the need for effective drug therapies.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 705.30 Million
Market Size 2030	USD 1061.82 Million
CAGR 2025-2030	7.20%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Key Market Drivers

Advancements in Treatment Options

Innovative treatment modalities have significantly enhanced uveitis management in recent years. Biologics, such as adalimumab and infliximab, offer targeted therapy by modulating the immune response responsible for inflammation. Sustained-release corticosteroid implants, including dexamethasone-based options, have improved patient compliance by reducing the frequency of administration. Intravitreal injections and advanced topical formulations have gained popularity for delivering drugs directly to the affected area while minimizing systemic side effects. In March 2025, ANI Pharmaceuticals received FDA approval for an expanded indication of ILUVIEN (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis of the posterior segment (NIU-PS). This move reinforces the shift toward longer-lasting, targeted therapies in uveitis treatment. These developments underscore the growing availability of effective, patient-friendly options that are helping reshape the treatment landscape for this potentially sight-threatening condition.

Key Market Challenges

High Cost of Treatment

The cost burden associated with uveitis treatment continues to be a key constraint, especially in resource-limited settings. Advanced drugs such as biologics and intravitreal implants can be expensive, often exceeding affordability thresholds for uninsured or underinsured patients. Chronic disease management requires continuous medication, regular monitoring, and specialist consultations, all of which drive long-term healthcare expenditures. In many cases, limited access to eye care professionals and diagnostic facilities compounds these challenges, particularly in rural or underserved regions. High treatment costs may result in poor adherence or delayed treatment, thereby increasing the risk of complications and irreversible vision loss. Healthcare systems also face economic strain, with the rising prevalence of uveitis increasing demand for cost-intensive care. These barriers emphasize the urgent need for affordable treatment options, including the introduction of generics and biosimilars, to improve accessibility and reduce the financial burden on patients and providers alike.

Key Market Trends

Patient-Centric Approaches

A notable trend in the uveitis drugs market is the shift toward personalized, patient-centered care. Healthcare providers are tailoring treatment strategies based on disease subtype, severity, patient health status, and individual preferences. Shared decision-making between clinicians and patients fosters better adherence and outcomes. Enhanced patient education initiatives focus on raising awareness about uveitis symptoms, treatment importance, and disease monitoring. This approach is supported by the implementation of simplified treatment regimens and reminder systems to boost adherence. Emphasis is also placed on improving quality of life through comprehensive management plans that address the physical, psychological, and social effects of the disease. Access to educational resources and patient advocacy networks is helping individuals navigate the complexities of long-term disease management, creating a more engaged and informed patient base. These strategies reflect a broader healthcare trend focused on empowering patients and optimizing long-term outcomes.

Key Market Players

• Allergan Inc.
• Bausch & Lomb Incorporated
• Santen Pharmaceutical Co. Ltd
• AbbVie Inc.
• Novartis AG
• Eyegate Pharmaceuticals Inc.
• Regeneron Pharmaceuticals
• Eyepoint Pharmaceuticals Inc.
• Alimera Sciences Inc.

Report Scope:

In this report, the Global Uveitis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uveitis Drugs Market, By Treatment Type:

• Analgesics
• Antibiotics
• Antifungal
• Antivirals
• Corticosteroids
• Cycloplegic Agents
• Immunosuppressant
• Monoclonal Antibodies

Uveitis Drugs Market, By Disease Type:

• Anterior Uveitis
• Intermediate Uveitis
• Panuveitis
• Posterior Uveitis

Uveitis Drugs Market, By Cause:

• Infectious
• Noninfectious

Uveitis Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Uveitis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uveitis Drugs Market.

Available Customizations:

Global Uveitis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uveitis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Analgesics, Antibiotics, Antifungal, Antivirals, Corticosteroids, Cycloplegic Agents, Immunosuppressant, Monoclonal Antibodies)
  • 5.2.2. By Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis, Posterior Uveitis)
  • 5.2.3. By Cause (Infectious, Noninfectious)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Uveitis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Cause
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Uveitis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Cause
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Uveitis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Cause
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Uveitis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Cause
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Uveitis Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By Disease Type
      • 6.3.4.2.3. By Cause
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Uveitis Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By Disease Type
      • 6.3.5.2.3. By Cause
      • 6.3.5.2.4. By Distribution Channel

7. Europe Uveitis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Cause
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Uveitis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Cause
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Uveitis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Cause
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Uveitis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Cause
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Uveitis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Cause
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Uveitis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Cause
      • 7.3.5.2.4. By Distribution Channel

8. North America Uveitis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Cause
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Uveitis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Cause
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Uveitis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Cause
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Uveitis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Cause
      • 8.3.3.2.4. By Distribution Channel

9. South America Uveitis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Cause
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Uveitis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Cause
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Uveitis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Cause
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Uveitis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Cause
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Uveitis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Cause
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Uveitis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Cause
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Uveitis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Cause
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Uveitis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Cause
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Uveitis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Allergan Inc
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bausch & Lomb Incorporated
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Santen Pharmaceutical Co Ltd.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. AbbVie Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Novartis AG
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Eyegate Pharmaceuticals; Inc.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Regeneron Pharmaceuticals
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Eyepoint pharmaceuticals Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Alimera Sciences Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료